Integra Lifesciences Holdings

IART · NASDAQ

$13.33−$0.12 (−0.89%)TodayMarket closed · Oct 20, 7:49 PM ET

Prev close $13.45

IART analyst rating

HoldConsensus of 7 analysts over the last 12 months. 0% rate it a buy.

Strong buy0
Buy0
Hold6
Underperform1
Sell0

12-month price target · 11 analysts

Average $20.27 (+52.1% upside)

Low: $14.14
Now: $13.33
High: $28.35

Upgrades and downgrades

The latest rating actions, newest first

IART analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
Truist Securities	Oct 14, 2026	Maintains	Hold	$19.00 → $15.00	33%
Citigroup	Oct 5, 2026	Maintains	Neutral	$19.00 → $15.00	60%
BMO Capital	Oct 5, 2026	Maintains	Market Perform	$18.00 → $15.00	45%
Wells Fargo	Jul 30, 2026	Maintains	Equal-Weight	$15.00 → $18.00	54%
UBS	Jul 28, 2026	Initiates	Neutral	$19.00	43%
Truist Securities	Jul 16, 2026	Maintains	Hold	$14.00 → $19.00	33%
BMO Capital	Jul 9, 2026	Initiates	Market Perform	$19.00	45%
Citigroup	Jul 8, 2026	Maintains	Neutral	$16.00 → $19.00	60%
Citigroup	May 28, 2026	Upgrade	Sell → Neutral	$11.00 → $16.00	60%
Citigroup	May 6, 2026	Maintains	Sell	$9.00 → $11.00	60%

The case for and against

Updated Oct 22, 2025

Bull case

Integra Lifesciences Holdings Corp has demonstrated a strong demand trajectory, particularly within its Neurosurgery portfolio, with notable double-digit growth in key product lines such as Georgian and Mayfield capital equipment. The company's Instruments subsegment achieved significant revenue growth of 15.1% year-over-year, highlighting its effective positioning in the medical equipment sector. While the Wound Reconstruction segment faced a decline due to production timing, the overall performance metrics indicate a resilient and growing business foundation for Integra in diverse markets.

Bear case

Integra Lifesciences Holdings Corp is experiencing significant profitability challenges, reflected in an expected adjusted EPS of $0.40-$0.45, which represents a decline of approximately 23% year-over-year at the midpoint. Additionally, international sales have decreased in low double digits compared to the prior year, indicating ongoing market difficulties and concerns related to operational adjustments. The company's gross margin has also contracted to 62.2%, down about 220 basis points year-over-year, primarily due to manufacturing variances and supply challenges, raising further concerns regarding future financial stability.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.